DraftKings Inc vs Mesoblast Limited — how do they compare? DraftKings Inc trades at $25.14 (market cap $12.05B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: DraftKings Inc is far larger — about 5.6× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals.
| DKNG | MESO | |
|---|---|---|
Market Cap | $12.05B | $2.16B |
Sector | Consumer Cyclical | Technology |
52-Week High | $48.23 | $20.96 |
52-Week Low | $20.72 | $12.88 |
Enterprise Value | $12.98B | $2.17B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Trailing returns across standard periods
Latest headlines on both assets
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →